dpp-4 inhibitor and glp-1 receptor agonist combination Inhibitors: What Is Their Place in Therapy? DPP4 Inhibitors vs GLP-1 Agonists

doi: 10.1097/MCO.0b013e32835ad2ee 18 BertoniG.TrevisiE.HanX.BionazM

Recently published efficacy and safety data are reviewed and the potential role of this novel GLP-1 receptor agonist in patient care is discussed

Peptide Vials (SS31, 10 mg each): 8 weeks (Standard: 510 mg/day) 50 vials 12 weeks (Standard maintenance at 10 mg/day) 77 vials 12 weeks (Advanced: escalating to 15 mg/day) 105 vials Insulin Syringes (U100, 1 mL capacity): Per week (standard dosing): 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes Advanced protocols with split injections may require 2 syringes per day for higher doses Bacteriostatic Water (30 mL bottles): Use 1.0 mL per vial for reconstitution

and Physiology 34 (4), 318326

J Periodont Res

Moreover, Glutathione 6% Nasal Spray has been found effective in reducing mucus production, a common symptom in chronic obstructive pulmonary disease and cystic fibrosis